Leal combines human genetic and biomarker support with CNS medicinal chemistry and oligonucleotide experience. That mix lets it pursue first-in-class metabolic targets that many psychiatric drugs do not address.
LTX-001 is designed for a broader efficacy and safety profile than dopamine- or muscarinic-only schizophrenia drugs. LTX-002 is intended for a wider ALS population than mutation-restricted antisense therapies such as SOD1-only treatments.
Schizophrenia, bipolar disorder, major depression, ALS, and Alzheimer's disease remain areas of high unmet need where existing drugs often treat symptoms or serve narrow genetic subsets.
Leal's 2026 clinical plans place LTX-001 in a Phase 1b/2a schizophrenia study and LTX-002 in a Phase 1/2 ALS study. Those readouts will determine whether neuro-metabolic correction can move from biomarker support into broader late-stage development.
Leal's pipeline targets metabolic drivers of CNS disease rather than only receptor-level symptoms. Lead programs are LTX-001, an oral glutaminase inhibitor, and LTX-002, an antisense oligonucleotide against SPTLC1.
Additional small-molecule SPT inhibitors, LTX-007 and LTX-008, are in candidate selection for Alzheimer's disease, rare sphingolipidoses, and metabolic disease. Delivery work includes brain-penetrant oral chemistry and antibody-like shuttles for nucleic acids.
